Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
about
TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cellsNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originErbB polymorphisms: insights and implications for response to targeted cancer therapeuticsThermodynamics of antibody-antigen interaction revealed by mutation analysis of antibody variable regions.Using simple artificial intelligence methods for predicting amyloidogenesis in antibodiesNimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II studyNimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer PatientsExperimental approaches for the treatment of malignant gliomas.Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.Prediction and analysis of antibody amyloidogenesis from sequences.On the training of young doctors in China.Towards the molecular characterization of the stable producer phenotype of recombinant antibody-producing NS0 myeloma cells.Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for ImmunotherapyA pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinomaTargeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody.New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.A view on EGFR-targeted therapies from the oncogene-addiction perspective.Therapeutic approaches to target cancer stem cells.Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity.Nimotuzumab in pediatric glioma.Dose-Dependent Induction of an Idiotypic Cascade by Anti-Glycosaminoglycan Monoclonal Antibody in apoE-/- Mice: Association with Atheroprotection.Targeting the epidermal growth factor receptor in solid tumor malignancies.Recombinant IgE antibody engineering to target EGFR.Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities.Validation of a flow cytometry based binding assay for evaluation of monoclonal antibody recognizing EGF receptor.CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.Anti-EGFR Agents: Current Status, Forecasts and Future Directions.Recent progress in protein-protein interaction study for EGFR-targeted therapeutics.Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor.Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancerComparative in vitro and experimental in vivo studies of the anti-epidermal growth factor receptor antibody nimotuzumab and its aglycosylated form produced in transgenic tobacco plants.Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody.Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer.The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck
P2860
Q24301702-9D18F7E9-2E18-40A6-AB30-811198B861AAQ24645217-ED9F93EE-80AF-4F21-AD3B-E815B4FDADC5Q28084565-7C5199D5-7504-4055-A0A1-18E773E09431Q30374518-496B1F06-1B5B-448F-8D0A-7045A43F8320Q30500316-2711606A-2654-488C-A5BB-2C2F4D848EFAQ33631435-B85A97FE-8948-4475-8CBA-A8AF17D9C3C3Q33779303-B60F0FCC-0E22-4844-B3D5-446CE078F3FCQ33809528-6EF06B98-9014-4DCD-9AA0-9BE80D20A151Q34127138-E86216E3-56EE-46DE-8ECD-F74FAA37F388Q34223866-FB4559F9-7E60-4A71-848B-1B93462DB122Q34343043-FBF3756D-C38F-420B-818C-0D129A4B7C81Q34544805-3F5B86EE-8125-4EE2-BC52-6462169AC271Q35032925-B92F16EB-D1C7-48CD-9364-E7DCE14524F1Q35119745-0226ADC6-6E2B-4893-9320-9C99C4546651Q35142705-8A96A03B-78AF-40F1-BA71-AC7F5D8EEF84Q35623476-6CD8BEF6-61F9-4997-AC8D-0E447D5C88B1Q35667892-9BC69EDF-68A1-41EA-A15C-B92CAFCB30CBQ36212978-5B102DD1-461F-498F-95D3-C3DB46058476Q36303845-B4874BC3-E90B-4278-92F5-CDAC70B3646FQ36304631-C98BC8B8-21D4-49B2-9F07-586983070FF8Q36795486-B1E33523-6510-47A4-8949-C5CE40FA6AEBQ37137412-1D9A2E76-DF5B-4D62-8881-B325BDE8BF8DQ37141964-2C6C415C-1FD6-48DC-A2BD-71E310D0E740Q37558534-4DD58153-C2AF-418A-9B25-78A2ECC10B1FQ37630569-80E47869-B669-4B6A-A2C2-3E9E66FCCC6CQ37677964-82D863B1-23A1-4F77-AAF3-698553A6CDCCQ37990044-A85012C4-2C5F-41AA-BDF3-6BA614ED5B11Q38016758-77BE0729-8EFD-4FD8-9751-C873067C2B72Q38071119-E779E19F-2F76-4D44-BFE4-798BDAF7A668Q38127413-1862F778-0976-4A65-B0B1-E11A1A62FEBAQ38268637-925FC764-0A23-4AF3-B600-D5B28E5630BEQ38341487-81B8F94D-DFD0-478F-92EB-694D63ACAC47Q38832105-8C37EF74-0720-4078-9C52-2E3FB7FDF890Q38899428-288B6CA1-1E3E-4D26-A227-D6DE55F0996BQ39052926-CA056A22-127E-4CC8-960E-3246DDBE287DQ39139857-EE7F31A3-AA1A-4244-B1E9-60D6805E6502Q39263753-45F8223A-0747-4D2C-82AD-7A715AF6C965Q40331204-792A71A9-5026-4AC8-9072-D55232AFA752Q41245735-C8D2F908-5BFA-4013-8B79-A3F41C592E79Q41513098-1740C9D5-302A-4C40-9992-8D66FB081554
P2860
Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
description
1997 nî lūn-bûn
@nan
1997 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մարտին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Humanization of a mouse monocl ...... very of antagonistic activity.
@ast
Humanization of a mouse monocl ...... very of antagonistic activity.
@en
Humanization of a mouse monocl ...... very of antagonistic activity.
@nl
type
label
Humanization of a mouse monocl ...... very of antagonistic activity.
@ast
Humanization of a mouse monocl ...... very of antagonistic activity.
@en
Humanization of a mouse monocl ...... very of antagonistic activity.
@nl
prefLabel
Humanization of a mouse monocl ...... very of antagonistic activity.
@ast
Humanization of a mouse monocl ...... very of antagonistic activity.
@en
Humanization of a mouse monocl ...... very of antagonistic activity.
@nl
P2093
P1476
Humanization of a mouse monocl ...... very of antagonistic activity.
@en
P2093
P356
10.1016/S1380-2933(97)00065-1
P577
1997-03-01T00:00:00Z